Dutasteride: Nursing Drug Guide, Fetal Exposure Risk & NCLEX Review

Dutasteride is available as a generic soft gelatin capsule and under the brand name Avodart. A fixed-dose combination with tamsulosin is also marketed (dutasteride 0.5 mg plus tamsulosin 0.4 mg once daily). Verify the MAR matches the dispensed product—monotherapy strength is 0.5 mg per capsule.

Do not confuse dutasteride with finasteride (another 5α-reductase inhibitor) or with alpha-blockers used for the same urinary symptoms. Both dutasteride and finasteride share pregnancy contraindications and PSA effects but differ in isoform inhibition and pharmacokinetics per labeling.

Dutasteride is indicated for men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate—to improve symptoms, reduce the risk of acute urinary retention, and reduce the need for BPH-related surgery per AVODART prescribing information.

It may be used alone or in combination with an alpha-adrenergic antagonist such as tamsulosin for symptomatic BPH. AVODART is not approved for prostate cancer prevention; 5α-reductase inhibitors may increase the risk of high-grade prostate cancer—labeling advises considering other urological diagnoses that mimic BPH symptoms before starting therapy.

↔On a small screen, swipe or scroll sideways to see the full table.

Prostate growth depends on dihydrotestosterone (DHT). Dutasteride inhibits both type 1 and type 2 5α-reductase, blocking conversion of testosterone to DHT and lowering serum DHT by about 85–90% within 1–2 weeks at the 0.5 mg daily dose per AVODART labeling.

With less DHT, prostate volume shrinks over months—many men need at least 6 months of therapy before benefit is clear. Median serum testosterone may rise while remaining in the physiologic range. Because DHT supports normal male external genital development in utero, fetal exposure carries teratogenic risk—this mechanism drives the pregnancy contraindication and transdermal handling warnings.

Monotherapy: 0.5 mg (one capsule) orally once daily. With tamsulosin: dutasteride 0.5 mg once daily plus tamsulosin 0.4 mg once daily. Swallow capsules whole; do not chew or open. May take with or without food (maximum serum concentrations reduced 10–15% with food—not clinically significant per labeling).

Institutional protocols and product formulations may vary.

Pretreatment checks

• Confirm male patient and correct indication (symptomatic BPH)—not indicated for women or children
• Ask about household contacts who are pregnant or may become pregnant; plan safe capsule storage and handling
• Baseline PSA and prior urology history—establish new PSA baseline ≥3 months after starting therapy
• Review allergy history to dutasteride, finasteride, or other 5α-reductase inhibitors
• Planned blood donation, fertility goals, and concurrent alpha-blocker or other BPH medications on the MAR

Contraindications

• Pregnancy—dutasteride may cause fetal harm; contraindicated in women who are pregnant
• Previously demonstrated clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors

Important warnings (labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

Selected interactions

Labeling notes dutasteride is extensively metabolized by CYP3A4 and CYP3A5. Use caution with potent CYP3A4 inhibitors—specific dose adjustments are not specified in the reviewed prescribing information; consult pharmacy and current labeling for individual agents.

• Follow medication administration rights—oral capsule given whole with water
• Do not open, chew, or crush soft gelatin capsules—opening increases exposure risk to handlers
• If administering via enteral tube is requested, not specified in the reviewed prescribing information—clarify with pharmacy rather than crushing
• Store securely away from pregnant household members and children
• Document education on handling, PSA testing, and blood donation deferral

Symptom improvement may begin before 3 months, but labeling notes a treatment period of at least 6 months is usually needed to judge benefit. Prostate volume reduction and improved urinary flow may accompany decreased urinary frequency, weak stream, or urinary incontinence in some patients.

Track urinary output, retention episodes, and symptom scores per clinic protocol. PSA should fall—use adjusted interpretation, not untreated reference ranges alone.

• Pregnant or possibly pregnant person exposed to dutasteride (ingestion, leaking capsule, significant skin contact)—wash contact area; urgent prescriber and maternal–fetal risk guidance per facility protocol
• Facial or tongue swelling, difficulty breathing, or serious skin reaction—suspect anaphylaxis or angioedema; emergency pathway
• Confirmed PSA increase from lowest value on dutasteride—evaluate for prostate cancer even if “normal” for untreated men
• Acute urinary retention, hematuria, or systemic symptoms suggesting infection or obstruction—urgent urology assessment
• New severe breast lump, nipple discharge, or persistent breast pain—report per labeling breast-disorder monitoring
• Suspected overdose—supportive care; no specific antidote; long half-life

Most common adverse reactions (≥1% and more frequent than placebo) per AVODART labeling: impotence, decreased libido, ejaculation disorders, and breast disorders (enlargement, tenderness). In combination with tamsulosin, ejaculation disorders and dizziness were also common.

↔On a small screen, swipe or scroll sideways to see the full table.

Labeling states sexual adverse reactions may persist after discontinuation; the role of dutasteride in persistence is unknown. Postmarketing hypersensitivity (rash, pruritus, urticaria, angioedema) is reported.

Volunteer studies administered single dutasteride doses up to 40 mg (80 times the therapeutic dose) for 7 days without significant safety concerns; 5 mg daily for 6 months did not add adverse effects beyond 0.5 mg per labeling.

There is no specific antidote for dutasteride. Provide symptomatic and supportive treatment, accounting for the long elimination half-life (approximately 5 weeks at steady state; serum detectable 4–6 months after stopping).

For suspected overdose, contact local poison control or toxicology services and emergency care per facility protocol—not country-specific hotlines in patient-facing teaching.

• Dutasteride vs finasteride—both 5α-reductase inhibitors for BPH; verify name, strength (0.5 mg vs finasteride 5 mg), and indication on MAR and blister pack
• Avodart vs Jalyn—combination dutasteride/tamsulosin vs monotherapy; confirm correct single product
• Do not crush or open capsules—LASA risk includes exposing pregnant staff or family to drug through skin
• Use medication reconciliation at transitions—duplicate 5α-reductase inhibitors must be caught
• Barcode scan when available; store away from look-alike hormone or prostate medications

• Ask privately about sexual function and mood—many patients do not volunteer impotence or libido changes
• If combination with tamsulosin, assess orthostatic symptoms when standing—first-dose syncope risk is mainly with alpha-blockers
• Remind patients swallowing whole avoids exposing partners or staff to capsule contents
• Clarify when PSA blood draw is due and that the lab result must be interpreted on therapy
• Flag planned blood drives—6-month deferral after last dose

• Household pregnancy exposure—partners, daughters, or staff who are pregnant must not handle capsules
• Fertility planning—semen parameters may decline; effects on individual fertility unknown per labeling
• Elevated baseline PSA or prior negative biopsy—cancer detection requires adjusted PSA thresholds and urology follow-up
• Hepatic impairment—not studied; potential for higher exposure
• Geriatric men—no overall efficacy difference in labeling, but polypharmacy increases interaction review needs

↔On a small screen, swipe or scroll sideways to see the full table.

Vitals: routine per setting; if on tamsulosin combo, document orthostatic blood pressure when dizziness reported. Labs beyond PSA: not specified in the reviewed prescribing information for routine monitoring—follow urology and primary care plans.

• Swallow the capsule whole—do not chew, open, or crush
• Pregnant women must not touch your capsules; if a capsule leaks, wash skin with soap and water immediately
• PSA tests will look lower on this medicine—always tell providers and labs you take dutasteride
• Do not donate blood for at least 6 months after your last dose
• Report breast changes, allergic swelling, urinary retention, or worsening voiding symptoms promptly
• Discuss sexual side effects openly—changes may continue after stopping; prescriber may adjust therapy
• AVODART is not for prostate cancer prevention and may increase high-grade cancer detection—keep scheduled urology follow-up
• If trying to conceive, discuss semen effects and timing with the prescriber

Do not give and contact the prescriber or pharmacist when:

Hold parameters may vary by institutional protocol. Because of the long half-life, effects persist weeks to months after the last dose—pharmacy should guide restart timing.

Rehearse NCLEX-style clinical judgment practice for dutasteride using a tabbed outpatient case (MAR · Labs · History · Nursing notes) focused on pregnancy exposure and PSA surveillance, then work through priority action, SATA cue recognition, PSA trend interpretation, ordered exposure-response steps, overdose-management cloze, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.

Unfolding case. Harold is a 71-year-old with BPH on dutasteride 0.5 mg daily for 8 months. His daughter, who is 12 weeks pregnant, opened a cracked capsule from his pill organizer while helping with medications. Clinic staff ask you to review the case tabs before today’s dose.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.